Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Viloxazine extended-release is a novel nonstimulant under investigation as a potential treatment for attention-deficit/hyperactivity disorder (ADHD). Given the potential for viloxazine extended-release to be co-administered with stimulant ADHD pharmacotherapies, this trial investigated the pharmacokinetics and safety of combination viloxazine extended-release + lisdexamfetamine dimesylate (lisdexamfetamine) versus viloxazine extended-release and lisdexamfetamine alone. Methods: In this single-center, cross-over, open-label trial, healthy, non-ADHD adults received single oral doses of 700 mg viloxazine extended-release alone, 50 mg lisdexamfetamine alone, and a combination of viloxazine extended-release (700 mg) + lisdexamfetamine (50 mg), with blood samples collected over 4 days postadministration. The active drug in viloxazine extended-release (viloxazine) and primary metabolite of lisdexamfetamine (d -amphetamine) were measured using chromatographic tandem mass spectrometry. Safety assessments included adverse events, vital signs, echocardiograms, and clinical laboratory evaluations. Results: Thirty-six adults were enrolled, and 34 completed the trial. The least squares geometric mean ratios are reported as [combination / single drug (90% confidence intervals)]. Viloxazine extended-release: C max = 95.96% (91.33–100.82), area under the concentration–time curve from 0 to the last measurable time (AUC 0-t) = 99.19% (96.53–101.91), and area under the concentration–time curve from 0 to infinity (AUC inf) = 99.23% (96.61–101.93). Lisdexamfetamine: C max = 112.78% (109.93–115.71), AUC 0-t = 109.64% (105.25–114.22), and AUC inf = 109.52% (105.19–114.03). All reported adverse events, except 1 (moderate vomiting), were mild in severity. Conclusions: Co-administration of viloxazine extended-release and lisdexamfetamine did not impact the pharmacokinetics of viloxazine or d -amphetamine relative to administration of either drug alone. After single dose administration, the combination appeared to be safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601
Danielson, M. L., Bitsko, R. H., Ghandour, R. M., Holbrook, J. R., Kogan, M. D., & Blumberg, S. J. (2018) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2017.1417860 · Cited by 1,181
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature
WILENS, T. E., ADLER, L. A., ADAMS, J., SGAMBATI, S., ROTROSEN, J., SAWTELLE, R., UTZINGER, L., & FUSILLO, S. (2008) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31815a56f1 · Cited by 824 · cited 1×
“However, stimulants may be contraindicated in patients with other conditions (eg, insomnia, anorexia, bipolar disorders, cardiovascular abnormalities such as hypertension or arrythmias), have a generally short (eg, 3–12 hours) duration of action,(17) and the potential for abuse and diversion.(18,19) Most frequently, c…”
BackgroundCatalá-López, F., Hutton, B., Núñez-Beltrán, A., Page, M. J., Ridao, M., Macías Saint-Gerons, D., Catalá, M. A., Tabarés-Seisdedos, R., & Moher, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180355 · Cited by 396
The Potential for Misuse and Abuse of Medications in ADHD: A Review
Clemow, D. B., & Walker, D. J. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2801 · Cited by 198
Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine
Pennick (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s9749 · Cited by 170 · cited 2×
“Lisdexamfetamine metabolism begins with PEPT1-mediated transport in the small intestine, where it is absorbed into portal circulation, and subsequently undergoes enzymatic hydrolysis of the parent molecule into the active metabolite D-amphetamine.(32) Although lisdexamfetamine itself is not metabolized by CYP enzymes,…”
BackgroundYu, C., Garcia-Olivares, J., Candler, S., Schwabe, S., & Maletic, V. (2020) · Journal of Experimental Pharmacology · doi:10.2147/jep.s256586 · Cited by 96 · cited 1×
“SPN-812 (viloxazine extended-release) has a novel, multimodal mechanism of action, with demonstrated activity at serotonin receptors and the norepinephrine transporter.(20) The original, immediate-release viloxazine formulation was approved in Europe as an antidepressant in 1974 and marketed for 28 years, before being…”
BackgroundSelf-citationJohnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H. (2020) · Journal of Attention Disorders · doi:10.1177/1087054719836159 · Cited by 62
Self-citation
Cited by
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066988 · Cited by 111
“Initially, Viloxazine or SPN-812 had been developed and approved in the UK for the treatment of depression, but later it was withdrawn from the market because of business reasons unrelated to the therapeutic effectiveness of the drug or its safety (Faison et al., 2021).”
BackgroundViloxazine: Pediatric First Approval
Lamb, Y. N. (2021) · Pediatric Drugs · doi:10.1007/s40272-021-00453-3 · Cited by 29
Nonstimulant Treatments for ADHD
Newcorn, J. H., Krone, B., & Dittmann, R. W. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.03.005 · Cited by 29
Maletic, V., Mattingly, G. W., & Earnest, J. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2327533 · Cited by 2
Self-citation
Metadata
- Authors
- Faison, S. L., Fry, N., Adewole, T., Odebo, O., Wang, Z., Maletic, V., & Nasser, A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2021-02-12
- Volume
- 41
- Issue
- 2
- Pages
- 155-162
- ISSN
- 0271-0749 (ISSN-L)
- 1533-712X
- OpenAlex
- W3129861271
- Cited by
- 28
- References
- 9
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. https://app.cochat.ai/papers/10.1097/jcp.0000000000001361
- The paper
- Faison, S. L., Fry, N., Adewole, T., Odebo, O., Wang, Z., Maletic, V., & Nasser, A. (2021). Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000001361
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.